Celldex CEO granted 375,000 stock options

Celldex Therapeutics, Inc. reported that President and CEO Anthony S. Marucci received a grant of 375,000 Incentive Stock Options to buy Celldex common stock at an exercise price of $34.09 per share under the company’s 2021 Omnibus Equity Incentive Plan.

Rhea-AI Filing Summary

Celldex Therapeutics, Inc. reported that President and CEO Anthony S. Marucci received a grant of 375,000 Incentive Stock Options to buy Celldex common stock at an exercise price of $34.09 per share under the company’s 2021 Omnibus Equity Incentive Plan.

These options start vesting with 25% becoming exercisable on June 25, 2027, and the remaining 75% vesting in equal quarterly installments over the following 12 quarters. The options expire on June 25, 2036. This is a compensation-related award, not an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 375,000 shares

Grant/Award 1 txn

Insider Marucci Anthony S

Role PRESIDENT & CEO

Type	Security	Shares	Price	Value
Grant/Award	Incentive Stock Option (right to buy)	375,000	$0.00	$0.00

Holdings After Transaction: Incentive Stock Option (right to buy) — 375,000 contracts (Direct)

Footnotes (2)

1. F1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
2. F2. 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Key Figures

Options granted: 375,000 options Exercise price: $34.09 per share Initial vesting date: June 25, 2027 +3 more

6 metrics

Options granted 375,000 options Incentive Stock Option grant to CEO Anthony S. Marucci

Exercise price $34.09 per share Exercise price for Incentive Stock Options on Celldex common stock

Initial vesting date June 25, 2027 25% of the option grant vests on this date

Subsequent vesting period 12 quarters Remaining 75% vests in equal quarterly installments

Expiration date June 25, 2036 Final expiration of the Incentive Stock Options

Options held after grant 375,000 options Total derivative securities following this reported transaction

Key Terms

Incentive Stock Option, 2021 Omnibus Equity Incentive Plan, vesting, exercise price

4 terms

Incentive Stock Option financial

"Incentive Stock Option (right to buy)"

An incentive stock option is a type of employee benefit that gives a worker the right to buy company shares at a fixed price, with special tax advantages if the employee holds the shares for a required period. Think of it as a coupon to buy future shares at today’s price that can result in lower tax on the gain. Investors care because ISOs can dilute share count, align staff incentives with the stock price, and affect company compensation costs and the timing of potential share sales.

2021 Omnibus Equity Incentive Plan financial

"option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan"

vesting financial

"25% vest on June 25, 2027 and the remainder vest quarterly"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise price financial

"conversion_or_exercise_price: 34.0900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Celldex (CLDX) CEO Anthony Marucci report in this Form 4?

Anthony S. Marucci reported receiving a grant of 375,000 Incentive Stock Options to buy Celldex common stock at $34.09 per share. The options were granted under the 2021 Omnibus Equity Incentive Plan as a compensation award, not through open-market trading.

What is the size and exercise price of the Celldex (CLDX) options granted to the CEO?

The grant covers 375,000 Incentive Stock Options with an exercise price of $34.09 per share. This means Marucci can buy up to 375,000 Celldex common shares at $34.09 once the options vest and before they expire.

How do the new Celldex (CLDX) CEO stock options vest over time?

The options vest over several years: 25% of the grant vests on June 25, 2027. The remaining 75% then vests in equal quarterly installments over the subsequent 12 quarters, creating a long-term incentive tied to continued service and company performance.

When do Anthony Marucci’s new Celldex (CLDX) stock options expire?

The granted Incentive Stock Options expire on June 25, 2036. Marucci must wait for the options to vest before exercising, and any unexercised vested options will lapse after that expiration date according to the award terms disclosed.

Is the Celldex (CLDX) Form 4 a stock purchase or sale by the CEO?

The Form 4 reports a grant of stock options as compensation, not a market purchase or sale. The transaction code is “A”, indicating a grant or award acquisition, and no open-market buying or selling of Celldex common stock is disclosed here.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:14 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Marucci Anthony S

(Last) (First) (Middle)

C/O CELLDEX THERAPEUTICS, INC.

53 FRONTAGE ROAD, SUITE 220

(Street)

HAMPTON NEW JERSEY 08827

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Celldex Therapeutics, Inc. [ CLDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Stock Option (right to buy)(1)	$34.09	06/25/2026(1)		A		375,000		06/25/2027(2)	06/25/2036	Common Stock	375,000	$0	375,000	D

Explanation of Responses:

1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

2. 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

	/s/ Sam Martin, attorney-in-fact for Anthony S. Marucci	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)